Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Tumor-associated fibroblasts are key regulators of tumorigenesis. In contrast to tumor cells, which are genetically unstable and mutate frequently, the presence of genetically more stable fibroblasts in the tumor-stromal compartment makes them an optimal target for cancer immunotherapy. These cells are also the primary source of collagen type I, which contributes to decreased chemotherapeutic drug uptake in tumors and plays a significant role in regulating tumor sensitivity to a variety of chemotherapies. To specifically kill tumor-associated fibroblasts, we constructed an oral DNA vaccine targeting fibroblast activation protein (FAP), which is specifically overexpressed by fibroblasts in the tumor stroma. Through CD8+ T cell-mediated killing of tumor-associated fibroblasts, our vaccine successfully suppressed primary tumor cell growth and metastasis of multidrug-resistant murine colon and breast carcinoma. Furthermore, tumor tissue of FAP-vaccinated mice revealed markedly decreased collagen type I expression and up to 70% greater uptake of chemotherapeutic drugs. Most importantly, pFap-vaccinated mice treated with chemotherapy showed a 3-fold prolongation in lifespan and marked suppression of tumor growth, with 50% of the animals completely rejecting a tumor cell challenge. This strategy opens a new venue for the combination of immuno- and chemotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, depleting fibroblast activation protein (FAP)+ CAFs via a FAP vaccine decreases collagen density and improves chemoresistance in mouse models [99].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
The myofibroblast in wound healing and fibrocontractive diseases
Gabbiani, G. (2003) · The Journal of Pathology · doi:10.1002/path.1427 · Cited by 1,630
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Stromal Effects on Mammary Gland Development and Breast Cancer
Wiseman, B. S., & Werb, Z. (2002) · Science · doi:10.1126/science.1067431 · Cited by 923
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Baxter, L. T., & Jain, R. K. (1989) · Microvascular Research · doi:10.1016/0026-2862(89)90074-5 · Cited by 894
Cited by
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
“A number of studies have implicated CAFs in the capability to limit the impact on tumor growth and progression of cancer cell apoptosis (Kalluri and Zeisberg, 2006; Loeffler et al., 2006; Pietras and Ostman, 2010).”
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
“cell-mediated immune response and further inhibit tumor growth and metastasis [330].”
BackgroundTurning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,234
“As a result, the CAFs are killed, reducing the amount of type I collagen and improving drug delivery (Loeffler et al., 2006).”
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
“Also, an oral DNA vaccine directed against FAP-positive cells caused CD8+ T cell–mediated killing of CAFs and suppression of primary tumor growth and metastasis, accompanied by a greater intratumoral uptake of chemotherapeutic drugs and improved drug response (Loeffler et al., 2006).”
BackgroundLindner, T., Loktev, A., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 935
“Such targeting of the stromal cells has been done using a variety of molecules, including antibodies (16– 18), chimeric antigen receptor T cells (19,20), immunoconjugates (21), peptide–drug complexes bearing the consensus sequence for the enzymatic activity (22,23), vaccines (14,24), and small molecules for the inhibi…”
BackgroundDynamic interplay between the collagen scaffold and tumor evolution
Egeblad, M., Rasch, M. G., & Weaver, V. M. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.08.015 · Cited by 896
“As a result, the carcinoma-associated fibroblasts are killed, leading to a reduction in the amount of type I collagen in the tumors and improved drug delivery and efficacy of chemotherapy [80].”
BackgroundCancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0770-1 · Cited by 860
“Oncolytic adenovirus FAP deletion No Enhances anti-tumor immunity CRC Preclinical [118, 119]”
BackgroundCancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
“The combination of DNA vaccine chemotherapy is considered effective [104].”
BackgroundCold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Carcinoma-associated fibroblasts: orchestrating the composition of malignancy
Gascard, P., & Tlsty, T. D. (2016) · Genes & Development · doi:10.1101/gad.279737.116 · Cited by 732
“Although antibodies targeting FAP are promising candidate drugs in animal models (Loeffler et al. 2006; Ostermann et al. 2008), clinical trials assessing twoantibodies (Table2)havenot shown the expected efficacy (Hofheinz et al. 2003).”
BackgroundFibrosis and cancer: A strained relationship
Piersma, B., Hayward, M.-K., & Weaver, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188356 · Cited by 680
“CAF depletion using CD8+ T cell-mediated killing of FAP+ CAFs suppressed primary breast and colon tumor growth and metastasis in experimental models [175].”
Bremnes, R. M., Dønnem, T., Al-Saad, S., Al-Shibli, K., Andersen, S., Sirera, R., Camps, C., Marinez, I., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f8a1bd · Cited by 691
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Monteran, L., & Erez, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01835 · Cited by 675
Stromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671
“An anti-FAP vaccine CAFs Breast Preclinical [5]”
InfluentialThe role of stroma in pancreatic cancer: Diagnostic and therapeutic implications
Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., & Friess, H. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.115 · Cited by 662
Fiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G., & De Maria, R. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0994-2 · Cited by 647
“Remarkably, combining FAP vaccination with chemotherapy yielded up to 70% greater uptake of chemotherapeutic drugs in tumor xenografts [110].”
BackgroundWang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0027 · Cited by 653
“analyses and showed that there was no significant inhibition of wound healing (28, 29).”
BackgroundImmune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
The role of fibroblast activation protein in health and malignancy
Fitzgerald, A. A., & Weiner, L. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09909-3 · Cited by 589
“Prophylactic vaccination with a DNA vaccine directed against FAP in mice inoculated with colon or breast carcinoma cells resulted in decreased tumor growth, suppressed pulmonary metastasis, increased chemotherapy uptake, and increased survival in a CD8+ T cell-dependent manner [148, 149].”
BackgroundFibroblasts as immune regulators in infection, inflammation and cancer
Davidson, S., Coles, M., Thomas, T., Kollias, G., Ludewig, B., Turley, S., Brenner, M., & Buckley, C. D. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00540-z · Cited by 605
Cancer-associated fibroblasts in gastrointestinal cancer
Kobayashi, H., Enomoto, A., Woods, S. L., Burt, A. D., Takahashi, M., & Worthley, D. L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0115-0 · Cited by 589
Mechanoreciprocity in cell migration
van Helvert, S., Storm, C., & Friedl, P. (2018) · Nature Cell Biology · doi:10.1038/s41556-017-0012-0 · Cited by 587
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
“20 The role of TGF-β signaling in angiogenesis is well recognized during ontogeny and in tumor growth.”
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Loktev, A., Lindner, T., Burger, E.-M., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Marmé, F., Jäger, D., Mier, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224469 · Cited by 554
Cancer-associated fibroblasts and tumor growth – bystanders turning into key players
Östman, A., & Augsten, M. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.01.003 · Cited by 543
“In this area FAP antibodies are the most mature candidate drugs, with documented effects in animal models [63 ,64].”
BackgroundImproving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
“Inhibition of FAP using an anti-tumor vaccine, monoclonal antibody, or chimeric antigen receptor (CAR) T-cell therapy, affects tumor cell growth and increases the CD8+ T cell response [207-209].”
BackgroundDrug Resistance Driven by Cancer Stem Cells and Their Niche
Prieto-Vila, M., Takahashi, R.-U., Usuba, W., Kohama, I., & Ochiya, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122574 · Cited by 508
“It is important to note that CAF not only induced drug resistance by promoting stemness signaling pathways in CSCs but also by secreting type I collagen, which contributes to decreasing drug uptake [115].”
BackgroundInfluentialCancer stem cell niche: the place to be
Borovski, T., De Sousa E Melo, F., Vermeulen, L., & Medema, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3220 · Cited by 518
“significantly reduced tumor growth and metastasis in, among others, colon cancer (34).”
BackgroundKemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 506
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3041 · Cited by 498
“Previous work employing anti-FAP vaccination resulted in decreased levels of collagen 1 and increased intratumoral uptake of chemotherapeutics (39).”
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 478
“impaired drug penetration through the extracellular matrix (ECM) influences drug response in primary solid tumors (Loeffler et al., 2006; Olive et al., 2009).”
BackgroundTran, E., Chinnasamy, D., Yu, Z., Morgan, R. A., Lee, C.-C. R., Restifo, N. P., & Rosenberg, S. A. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130110 · Cited by 463
“Accordingly, many groups have attempted to eradicate transformed cells by targeting fibroblast activation protein (FAP)-expressing stromal cells (Lee et al., 2005; Loeffler et al., 2006; Ostermann et al., 2008; Liao et al., 2009; Santos et al., 2009; Kraman et al., 2010; Wen et al., 2010).”
BackgroundZhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
“DNA vaccine can remarkably decrease stroma type I collagen expression and improve the efficacy of chemotherapy [215].”
BackgroundIshii, G., Ochiai, A., & Neri, S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.07.007 · Cited by 434
“Furthermore, tumor tissue received FAP-vaccine revealed markedly decreased collagen type I expression and up to 70% greater uptake of chemotherapeutic drugs [65].”
BackgroundLiao, D., Luo, Y., Markowitz, D., Xiang, R., & Reisfeld, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007965 · Cited by 437
“and suppress primary tumor growth of non-metastatic murine colon and breast cancers”
BackgroundSelf-citationThe microenvironment in breast cancer progression: biology and implications for treatment
Place, A. E., Jin Huh, S., & Polyak, K. (2011) · Breast Cancer Research · doi:10.1186/bcr2912 · Cited by 413
Dudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
“Pericytes, fibroblasts, and other mesenchymal-lineage cells in the stroma may be valuable indirect targets for antiangiogenesis in tumors (Loeffler et al. 2006); however, hematopoietic cells, particularly those of the myelomonocytic lineages, have recently received great attention for this purpose (Murdoch et al.”
BackgroundEffector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 422
Nagasaki, T., Hara, M., Nakanishi, H., Takahashi, H., Sato, M., & Takeyama, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.748 · Cited by 385
“In fact, several studies have reported that IL-6 and fibroblasts represent potential therapeutic targets in several cancers (Loeffler et al, 2006; Mueller et al, 2007; Coward et al, 2011; Hsu et al, 2011).”
BackgroundPro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics
Puré, E., & Blomberg, R. (2018) · Oncogene · doi:10.1038/s41388-018-0275-3 · Cited by 391
Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy
Mai, Z., Lin, Y., Lin, P., Zhao, X., & Cui, L. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06697-4 · Cited by 398
“Combined with chemotherapy, this vaccine ampli fi es anti-tumor effects by increasing chemotherapy drug uptake and accumulation [145, 146].”
BackgroundJekyll and Hyde: the role of the microenvironment on the progression of cancer
Allen, M., & Louise Jones, J. (2011) · The Journal of Pathology · doi:10.1002/path.2803 · Cited by 375
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
“Furthermore, collagen type I secreted by CAF is related to a decrease in intratumor chemotherapeutic drug uptake, which results in resistance to chemotherapy [114, 115].”
BackgroundAntitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Kakarla, S., Chow, K. K., Mata, M., Shaffer, D. R., Song, X.-T., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.110 · Cited by 346
Hu, Y., Yan, C., Mu, L., Huang, K., Li, X., Tao, D., Wu, Y., & Qin, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125625 · Cited by 348
“CAFs are also reported to play significant roles in regulating tumor sensitivity to a variety of chemotherapies, and targeting them dramatically decreases the chemoresistance [5, 6].”
BackgroundMicroenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Microenvironmental regulation of cancer development
Hu, M., & Polyak, K. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.006 · Cited by 330
Stromal biology of pancreatic cancer
Chu, G. C., Kimmelman, A. C., Hezel, A. F., & DePinho, R. A. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21209 · Cited by 317
“Other approaches aim to disable PDACassociated fibroblasts including a vaccine against fibroblast activation protein that seems to improve the efficacy of chemotherapy by increasing intratumoral drug uptake [Loeffler et al., 2006].”
BackgroundPathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
“efficiency of chemotherapy by improving drug uptake in the tumors [113].”
BackgroundTargeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
“It has been established that a DNA vaccine exclusively targeting FAP could suppress primary and metastatic tumor growth, promote the uptake of chemotherapeutic drugs and prolong the survival of tumor-bearing mice primarily by inducing CD8+ T cell-mediated killing of CAFs [427, 428].”
BackgroundTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“For example, depleting fibroblast activation protein (FAP) CAFs via a FAP vaccine decreases collagen density and improves chemoresistance in mouse models [99].”
BackgroundDrug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
“target the CAFs in murine colon and breast carcinoma and found that the intratumoral drug accumulation increases up to 70% of drug uptake [109].”
BackgroundCAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer
Pereira, B. A., Vennin, C., Papanicolaou, M., Chambers, C. R., Herrmann, D., Morton, J. P., Cox, T. R., & Timpson, P. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.09.010 · Cited by 314
“decrease metastatic burden, and overcome immune tolerance in mouse models of colon, lung, and breast cancer [94,95].”
BackgroundBiomarkers for cancer-associated fibroblasts
Han, C., Liu, T., & Yin, R. (2020) · Biomarker Research · doi:10.1186/s40364-020-00245-w · Cited by 299
“In distinct murine tumor models, multiple strategies targeting FAP exhibited therapeutic effects, including genetic deletion [24], pharmacological inhibition (PT630, PT-100) [25, 26], a novel monoclonal antibody (mAb) FAP5-DM1 [27], conditional ablation of FAP CAFs using diphtheria toxin [28] or αFAP-PE38 [29], and ev…”
BackgroundCancer‐associated fibroblasts in breast cancer: Challenges and opportunities
Hu, D., Li, Z., Zheng, B., Lin, X., Pan, Y., Gong, P., Zhuo, W., Hu, Y., Chen, C., Chen, L., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12291 · Cited by 286
“Current research results show that these vaccines inhibit tumor growth, including breast cancer, by increasing the level of IFNγ and the number of CD8-positive T cells in tumor tissues [87, 324, 325].”
BackgroundBrennen, W. N., Isaacs, J. T., & Denmeade, S. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0340 · Cited by 289
Castells, M., Thibault, B., Delord, J.-P., & Couderc, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285
“The combination of such an anti-FAP vaccine with doxorubicin brought about an inhibition of tumor growth and complete tumor rejection in half of the tested mice whereas there was no survival with doxorubicin treatment alone [82].”
BackgroundTumor microenvironment promotes breast cancer chemoresistance
Mehraj, U., Dar, A. H., Wani, N. A., & Mir, M. A. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04222-w · Cited by 289
Fearon, D. T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0002 · Cited by 288
“An early study of the effects on tumor growth of targeting the FAPþ stromal cell was overly simplistic; it was based on an assumption that DNA vaccination with a plasmid construct expressing FAP would induce immune-dependent elimination of FAPþ stromal cells by cytolytic CD8þ T cells (16).”
BackgroundRegulation of the anti-tumour immune response by cancer-associated fibroblasts
Harper, J., & Sainson, R. C. A. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.005 · Cited by 268
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors
Miao, L., Lin, C. M., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.017 · Cited by 264
“Vitamin D Receptor (VDR) has also been shown to be overexpressed in the pancreatic stellate cells (PSC), an activated form of CAF in PDA.”
BackgroundInfluentialCancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 254
Extracellular matrix stiffness: Mechanisms in tumor progression and therapeutic potential in cancer
Zhang, M., & Zhang, B. (2025) · Experimental Hematology & Oncology · doi:10.1186/s40164-025-00647-2 · Cited by 269
Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H. (2019) · Cancers · doi:10.3390/cancers11091334 · Cited by 260
“Studies have demonstrated that CAF coculture increases the secretion of type I collagen, contributing to decreased drug uptake in breast cancer cell lines [84,85].”
BackgroundXiang, H., Ramil, C. P., Hai, J., Zhang, C., Wang, H., Watkins, A. A., Afshar, R., Georgiev, P., Sze, M. A., Song, X. S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0507 · Cited by 256
“Cancer Immunol Res; 8(4) April 2020 CANCER IMMUNOLOGY RESEARCH 440”
BackgroundMethodInfluentialFibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Mhaidly, R., & Mechta-Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 259
“Similarly, conditional depletion of FAP + stromal cells in a mouse model of pancreatic cancer re-sensitizes cancer cells to anti-PD-1 and anti-CTLA-4 immunotherapies [241].”
The immune landscape of esophageal cancer
Huang, T.-X., & Fu, L. (2019) · Cancer Communications · doi:10.1186/s40880-019-0427-z · Cited by 262
The Latest Developments in Imaging of Fibroblast Activation Protein
Altmann, A., Haberkorn, U., & Siveke, J. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244806 · Cited by 257
“Moreover, the combination of FAP vaccination and chemotherapy improved the antitumor response in murine CT26 colon carcinoma and D2F2 breast cancer models (29).”
BackgroundThe double edge sword of fibrosis in cancer
Chandler, C., Liu, T., Buckanovich, R., & Coffman, L. G. (2019) · Translational Research · doi:10.1016/j.trsl.2019.02.006 · Cited by 242
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Jiang, H., Hegde, S., & DeNardo, D. G. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2003-1 · Cited by 242
“In total, these approaches can induce T cell-mediated killing of FAP+ CAFs which results in decreased collagen density and increased T cell-mediated control of tumor progression [79].”
Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Musetti, S., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05893 · Cited by 239
Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity
Li, Y., Chen, W., Kang, Y., Zhen, X., Zhou, Z., Liu, C., Chen, S., Huang, X., Liu, H.-J., Koo, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42509-7 · Cited by 235
“For example, targeting fi broblast activation protein with pFap DNA vaccines can improve chemotherapy outcomes by increasing intratumoral drug uptake 8 ; degradation of tumor ECM with hyaluronidase 9 or collagenase 10 can improve intratumoral diffusion of nanoparticles (NPs)and drugs.”
Mhaidly, R., & Mechta‐Grigoriou, F. (2021) · Immunological Reviews · doi:10.1111/imr.12978 · Cited by 231
Zhen, Z., Tang, W., Wang, M., Zhou, S., Wang, H., Wu, Z., Hao, Z., Li, Z., Liu, L., & Xie, J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04150 · Cited by 219
Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 216
Targeting of activated fibroblasts for imaging and therapy
Lindner, T., Loktev, A., Giesel, F., Kratochwil, C., Altmann, A., & Haberkorn, U. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0069-0 · Cited by 205
Feng, B., Wu, J., Shen, B., Jiang, F., & Feng, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02599-7 · Cited by 210
“Targeting of FAP + CAFs by oral DNA vaccine increases the intratumoral infiltration of both CD8 + T cells and chemotherapeutic drugs in multi-drug-resistant breast and colon cancer [127, 128].”
BackgroundIntegrin Signaling in Cancer Cell Survival and Chemoresistance
Aoudjit, F., & Vuori, K. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/283181 · Cited by 205
“Targeting tumor-associated fibroblasts also improves cancer chemotherapy by increasing intratumoral drug uptake [167].”
BackgroundCancer-associated fibroblasts: A multifaceted driver of breast cancer progression
Luo, H., Tu, G., Liu, Z., & Liu, M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.018 · Cited by 204
“Accordingly, targeting CAFs increases intratumoral drug intake and suppresses primary tumor cell proliferation and metastasis of multidrug-resistant murine breast cancer [123].”
BackgroundCancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment
Houthuijzen, J. M., & Jonkers, J. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9768-3 · Cited by 205
Cremasco, V., Astarita, J. L., Grauel, A. L., Keerthivasan, S., MacIsaac, K., Woodruff, M. C., Wu, M., Spel, L., Santoro, S., Amoozgar, Z., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0098 · Cited by 207
“org Cancer Immunol Res; 6(12) December 2018 1481”
BackgroundInfluentialCancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 195
Ammirante, M., Shalapour, S., Kang, Y., Jamieson, C. A. M., & Karin, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416498111 · Cited by 206
“To deplete FAP cells in the androgen-deprived tumor stroma, we orally administered a DNA vaccine encoding FAP that is delivered to secondary lymphoid tissues by a noninfectious, attenuated, live Salmonella typhimurium vector (TOPO) (30).”
BackgroundMethodInfluentialHuang, T.-X., Tan, X.-Y., Huang, H.-S., Li, Y.-T., Liu, B.-L., Liu, K.-S., Chen, X., Chen, Z., Guan, X.-Y., Zou, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322924 · Cited by 200
“37 Therefore, employing a strategy of depleting WNT2-secreting CAFs in combination with PD-1 antibodies could not only work to improve antitumour immune responses but also enhance the infiltration of PD-1 antibodies into tumours.”
Invading one step at a time: the role of invadopodia in tumor metastasis
Paz, H., Pathak, N., & Yang, J. (2014) · Oncogene · doi:10.1038/onc.2013.393 · Cited by 197
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
Takai, K., Le, A., Weaver, V. M., & Werb, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12658 · Cited by 207
“While many studies have targeted angiogenesis and inflammation/immune function, several investigations recently have focused on stromal collagenous extracellular matrix and CAFs as potential targets [27, 47-58].”
BackgroundJanuškevičienė, I., & Petrikaitė, V. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117009 · Cited by 196
Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts
Avery, D., Govindaraju, P., Jacob, M., Todd, L., Monslow, J., & Puré, E. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.003 · Cited by 206
Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?
Belhabib, I., Zaghdoudi, S., Lac, C., Bousquet, C., & Jean, C. (2021) · Cancers · doi:10.3390/cancers13143466 · Cited by 191
“thus increasing the intratumor uptake of chemotherapeutic drugs [274].”
BackgroundXin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
Role of Oxidative Stress and the Microenvironment in Breast Cancer Development and Progression
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00003-4 · Cited by 200
Metadata
- Authors
- Loeffler, M.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Loeffler, M.
- ORCID
- Loeffler, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1955-1962
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1481657
- OpenAlex
- W2002689409
- Cited by
- 633
- References
- 51
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 41 · 2023: 58 · 2022: 33 · 2021: 56 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 32 · 2016: 39 · 2015: 46 · 2014: 33 · 2013: 33 · 2012: 28
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health
- National Cancer Institute (CA 83856, R01CA083856)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer-associated fibroblasts, fibroblast activation protein, oral DNA vaccine, type I collagen, tumor stroma, chemosensitization, multidrug resistance, colon cancer, breast cancer, metastasis, chemoimmunotherapy
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Female, Fibroblasts, Membrane Proteins, Mice, Inbred BALB C, Neoplasms, Endopeptidases, Recombinant Fusion Proteins, Serine Endopeptidases, Survival Rate, Gelatinases, CD8-Positive T-Lymphocytes, Vaccines, DNA, Cancer Vaccines, Collagen Type I, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.